Document Detail

Monotherapy treatment of paruresis with gabapentin.
MedLine Citation:
PMID:  15602118     Owner:  NLM     Status:  MEDLINE    
Paruresis, the difficulty or inability to urinate in the presence of others, is a highly prevalent (7-32%) social anxiety subtype that is both chronic and pervasive. Paruresis negatively impacts quality of life. Treatment strategies have focused on psychological interventions. To date, standard social anxiety pharmacotherapies utilized in the treatment of paruresis have shown minimal efficacy. A PUBMED search revealed no references to paruresis treatment with selective serotonin reuptake inhibitors or gabapentin. This case report presents the first instance of successful monotherapy treatment of paruresis with gabapentin. The patient's relative medicine noncompliance resulted in an on-off-on treatment design with a dose-dependent response. Efficacy persisted throughout a 7-month treatment course. Gabapentin should be studied further for its potential use in the treatment of paruresis.
Kenneth R Kaufman
Related Documents :
24508898 - Antibiotic use in dutch primary care: relation between diagnosis, consultation and trea...
8189008 - Helicobacter pylori-associated peptic ulcer in heterotopic gastric mucosa within ileal ...
6287928 - Prophylactic activity of intranasal enviroxime against experimentally induced rhinoviru...
18943598 - Spatial pattern analysis of citrus canker-infected plantings in são paulo, brazil, and ...
23446368 - Gram-negative diabetic foot osteomyelitis: risk factors and clinical presentation.
12368068 - Cidofovir in the therapy and short-term prophylaxis of poxvirus infections.
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  International clinical psychopharmacology     Volume:  20     ISSN:  0268-1315     ISO Abbreviation:  Int Clin Psychopharmacol     Publication Date:  2005 Jan 
Date Detail:
Created Date:  2004-12-16     Completed Date:  2005-05-10     Revised Date:  2013-06-11    
Medline Journal Info:
Nlm Unique ID:  8609061     Medline TA:  Int Clin Psychopharmacol     Country:  England    
Other Details:
Languages:  eng     Pagination:  53-5     Citation Subset:  IM    
Department of Psychiatry, UMDNJ-Robert Wood Johnson Medical School, New Brunswick, New Jersey 08901, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Amines / therapeutic use*
Anti-Anxiety Agents / therapeutic use*
Anxiety Disorders / complications,  drug therapy*,  psychology
Cyclohexanecarboxylic Acids / therapeutic use*
Dose-Response Relationship, Drug
Middle Aged
Patient Compliance
Treatment Outcome
Urination Disorders / drug therapy*,  psychology*
gamma-Aminobutyric Acid / therapeutic use*
Reg. No./Substance:
0/Amines; 0/Anti-Anxiety Agents; 0/Cyclohexanecarboxylic Acids; 56-12-2/gamma-Aminobutyric Acid; 6CW7F3G59X/gabapentin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Imputing response rates from means and standard deviations in meta-analyses.
Next Document:  Valproic acid-associated hyperammonemic encephalopathy: a case report from the psychiatric setting.